The McKinney, Texas-based orthopedic device manufacturer, which has operations in Springfield and Boston, said it paid down about $15 million in debt, including a $3 million payment it made ahead of schedule.
Image Diagnostics Inc., a maker of tables and monitor stands used in medical imaging, will be moving into a 38,000-square-foot manufacturing facility in Fitchburg.
The Sterling-based company said the move, financed in part by a $1.5 million tax exempt bond from MassDevelopment, will help create 10 new jobs.
Image Diagnostics operates out of an 11,000-square-foot building in Sterling.
The Waltham-based neurological testing equipment manufacturer posted sales of $6.8 million for the quarter, compared with $8.7 million for the same period last year. But 90 percent of those sales were derived from consumables, with medical equipment making up less than 10 percent.
Pressure BioSciences Inc. reported a 130 percent increase in first-quarter sales, as the lab equipment maker continues its efforts to reduce its net losses and cash burn and move from pure research to a sales-based business model.
The South Easton-based company, which specializes in sample preparation equipment for genomic and proteomic research, posted sales of about $307,000 for the three-month period ended March 31, up from nearly $133,000 during the same period last year.
Health Canada cleared the skin treatment device for distribution there, adding the country to the Wayland cosmetic laser treatment maker’s sales territories in the United States, Europe and Australia.
Instrumentation Laboratory landed 510(k) approval from the Food & Drug Administration for its ACL AcuStar hemostasis testing system, clearing the way for the immunoassay analyzer to hit the market.
IL said it will begin selling the device, which is a fully-automated hemostasis immunoassay analyzer that uses chemiluminescent markers, in Europe — and it will have some extra euros to spend on marketing.
The bad news for the Westford-based cosmetic laser firm is the 61 percent revenue plunge it posted for the three months ended March 31, slightly more than the 60 percent decrease it predicted.
First-quarter sales fell to $14.8 million, down from $36.7 million during the first quarter of 2008. The drop was enough to reverse a net gain of $4.8 million during the first three months of 2008 into a $4 million loss for the quarter.
The Marlborough-based molecular diagnostics firm, which is developing tests for colorectal cancer, posted sales of $1 million for the three months ended March 31, compared with $51,000 during the same period last year.
Sales and earnings continued to slide for NMT Medical Inc., as its hospital customers scaled back inventories in response to the down economy.
The Boston cardiac implant maker posted sales of $3.48 million for the three months ended March 31, down 27.9 percent compared with the same period last year.
NMT’s quarterly net loss widened by 2.2 percent, reaching $3.8 million compared with $3.9 million during the first quarter of 2008.
Company officials chalked up the slide to hospitals reducing their inventories, taking longer to re-order NMT’s non-invasive cardiac repair products and thereby lengthening its sales cycle.
“Flat is the new up these days.”
During a preliminary review of the consulting firm’s look at the medical device sector, “Pulse of the Industry,” Ramko said companies that manage to keep sales and earnings flat are doing well, given the economic realities.
“Companies are facing a lot of tough decisions,” Ramko told the audience at Boston’s John F. Kennedy Presidential Library & Museum. “It’s just a challenging time.”